LIPOCINE INC.: Lipocine Announces Trial Date in Lipocine's Infringement Lawsuit Against Clarus Therapeutics and Will Seek a Permanent Injunction

Lipocine Inc. issued the following announcement on Aug. 27.

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced today that the U.S. District Court of Delaware has set a trial date for Lipocine’s patent infringement lawsuit against Clarus’s JATENZO® drug product relating to six of Lipocine’s U.S. patents. Trial is set to begin August 24, 2020 at which time Lipocine plans to seek a permanent injunction for Clarus’s infringement.

"Lipocine has full confidence in its intellectual property and will continue to vigorously assert its infringement claims against Clarus," said Dr. Mahesh Patel, Chairman, President, and Chief Executive Officer of Lipocine.

Original source can be found here.

Source: Lipocine Inc. 

Want to get notified whenever we write about Lipocine Inc. ?

Sign-up Next time we write about Lipocine Inc., we'll email you a link to the story. You may edit your settings or unsubscribe at any time.

Organizations in this Story

Lipocine Inc.

More News

Metro Business Network